Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial.

ABSTRACT:

Aims/hypothesis

We aimed to determine the persistence of glycaemic control 1 year after a limited period of intensive glycaemic management of type 2 diabetes.

Methods

4119 ACCORD Trial participants randomised to target HbA1c <6.0% (42 mmol/mol) for 4.0 ± 1.2 years were systematically transitioned to target HbA1c 7.0-7.9% (53-63 mmol/mol) and followed for an additional 1.1 ± 0.2 years. Characteristics of participants with HbA1c <6.5% (48 mmol/mol) or ≥6.5% at transition were compared. Changes in BMI and glucose-lowering medications were compared between those ending with HbA1c <6.5% vs ≥6.5%. Poisson models were used to assess the independent effect of attaining HbA1c <6.5% before transition on ending with HbA1c <6.5%.

Results

Participants with pre-transition HbA1c <6.

SUBMITTER: Punthakee Z 

PROVIDER: S-EPMC4698982 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature